1. Volume 66, Issue 3, Pages 459-465 (September 2014)
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents 
Carmel J. Pezaro, Aurelius G. Omlin, Amelia Altavilla, David Lorente, Roberta Ferraldeschi, Diletta Bianchini, David Dearnaley, Christopher Parker, Johann S. de Bono, Gerhardt Attard 
European Urology 
Volume 66, Issue 3, Pages (September 2014)
DOI: /j.eururo
Copyright © 2013 European Association of Urology Terms and Conditions

2. Fig. 1
Waterfall plot showing maximum change (percentage) in prostate-specific antigen (PSA) level from baseline on abiraterone and cabazitaxel treatments. Paired bars represent individual patients. Stars represent patients exposed to enzalutamide prior to cabazitaxel. Increases in PSA level are capped at 50%.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions